Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)

University of Florida

Status: Withdrawn

Conditions: Prostate Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT03296124

IRB201700018 (Other Identifier)

UFPTI 1612- PRX32

Details and patient eligibility

About

Retrospective Review Study for Prognostic Transcriptional Output Related to Androgen Receptor Expression in Patients Treated for High Risk Prostate Cancer with Proton Therapy

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Adult patients (older than 18 years at time of treatment) with high risk prostate cancer who were treated with proton therapy at UFHPTI/Department of Radiation Oncology
• Patients treated between 6/10/2010 through 4/26/17 with at least 2 years follow up